Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Trastuzumab Emtansine Hormone Receptor Positive Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Emtansine Invasive Breast Lobular Carcinoma	Vanderbilt-Ingram Cancer Center	P2	CCC (53)
Trastuzumab Emtansine Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Lung Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Uterine Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Neoplasm	Seoul National University Bundang Hospital	P2	CCC (53)
Trastuzumab Emtansine Ovarian Cancer	OHSU Knight Cancer Institute	P2	CCC (53)
Trastuzumab Emtansine Pancreatic Ductal Carcinoma	University Health Network, Toronto	P2	CCC (53)
Trastuzumab Emtansine Progesterone-Receptor Negative Breast Cancer	Jules Bordet Institute	P2	CCC (53)
Trastuzumab Emtansine PR-Positive Breast Cancer	Massachusetts General Hospital	P2	CCC (53)
Trastuzumab Emtansine Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Recurrent Malignant Solid Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Skin Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Solid Tumor Cancers	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Trastuzumab Emtansine Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Trastuzumab Emtansine	The First Affiliated Hospital with Nanjing Medical University	P2	CCC (53)
Trastuzumab Emtansine Urinary System Neoplasm	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Zirconium Zr 89 Crefmirlimab Berdoxam Locally Advanced Solid Tumor	University Medical Center Groningen	P2	CCC (53)
Zirconium Zr 89 Crefmirlimab Berdoxam Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Olivia Newton-John Cancer Research Institute	P2	CCC (53)
rc48-adc Advanced Pancreatic Ductal Adenocarcinoma	Daniel Breadner	P1/2	CCC (53)
Zilovertamab Vedotin Burkitt Lymphoma	Merck Sharp & Dohme LLC	P1/2	CCC (53)
fda018-adc Triple-Negative Breast Carcinoma	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	P3	CCC (52)

Showing 501 to 525 of 1,027 assets

PreviousPage 21 of 42Next